In this issue:
Extrahepatic cancer risk linked to HCV or HBV cirrhosis
SIRT3 activators for preventing or treating HBV infection?
Sofosbuvir + NS5A inhibitor for recurrent HCV infection post-LT
Glecaprevir/pibrentasvir in chronic HCV GT 1–6 infection post-transplant
Treatment cost-effectiveness postresection in HBV-related HCC
Phenotypic markers in HCV-related cirrhosis predict HCC?
Sofosbuvir + velpatasvir ± ribavirin in HCV GT 3 infection and cirrhosis
Dramatic impact of DAAs on liver transplantation
A novel, simple diagnostic score selects for HBV treatment
Normal on-treatment ALT matters in chronic HBV infection
Please login below to download this issue (PDF)